Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Advanced Solid Tumors With HER2 Abnormalities Clear all

Terminated Phase 1 Interventional

A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

NCT03410927

View directory record Official record

Conditions: Advanced Solid Tumors With HER2 Abnormalities, Advanced Solid Tumors With HER3 Abnormalities
Interventions: TAS0728; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • New York, New York + 2 more

Source: ClinicalTrials.gov public record

Updated Sep 4, 2024 · Synced May 21, 2026, 7:19 PM EDT

Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844

View directory record Official record

Conditions: Advanced Solid Tumors, Advanced Breast Cancer
Interventions: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant; Drug
Lead sponsor: Ensem Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 21, 2026, 7:19 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

NCT07540572

View directory record Official record

Conditions: ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
Interventions: IDE574, Fulvestrant injection; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: East Brunswick, New Jersey • Lake Success, New York • Austin, Texas + 6 more

Source: ClinicalTrials.gov public record

Updated May 19, 2026 · Synced May 21, 2026, 7:19 PM EDT

Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139

View directory record Official record

Conditions: Breast Cancer, Solid Tumors, Adult
Interventions: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more

Source: ClinicalTrials.gov public record

Updated Apr 22, 2026 · Synced May 21, 2026, 7:19 PM EDT

Completed Phase 1 Interventional

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316

View directory record Official record

Conditions: Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions: AZD5363; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years

Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • West Hollywood, California + 8 more

Source: ClinicalTrials.gov public record

Updated Jun 28, 2025 · Synced May 21, 2026, 7:19 PM EDT